Additional factors that could improve cost-effectiveness of pharmacogenetic-guided dosing in warfarin therapy.
Geisler
Benjamin P
BP
Levin-Scherz
Jeffrey K
JK
D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000235:genetics*; D003362:Cost-Benefit Analysis; D005838:Genotype; D006801:Humans; D014859:Warfarin / Q000008:administration & dosage*
D000925:Anticoagulants; D014859:Warfarin